1. Candidate Angiogenesis‐Related Biomarkers in Patients with Laryngeal Carcinoma (AngLaC): A Prospective Cohort Study
   A. Erim Pamuk et al, 2023, Otolaryngology–Head and Neck Surgery CrossRef
2. RTKs in pathobiology of head and neck cancers
   Revathy Nadhan et al, 2020, Receptor Tyrosine Kinases CrossRef
3. Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations
   Stefan Holzhauser et al, 2021, Frontiers in Oncology CrossRef
4. Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
   Khine S. Shan et al, 2024, International Journal of Molecular Sciences CrossRef
5. The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy
   Mario Scheurer et al, 2019, International Journal of Molecular Sciences CrossRef
6. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines
   Ourania Kostopoulou et al, 2019, International Journal of Oncology CrossRef
7. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
   Yun Liu et al, 2022, Journal of Hematology & Oncology CrossRef
8. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer
   Zechen Wang et al, 2022, The Cancer Journal CrossRef
9. Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer
   Arielle Elkrief et al, 2020, Improving Outcomes in Oral Cancer CrossRef
10. Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas
    Gopika Senthilkumar et al, 2020, Improving the Therapeutic Ratio in Head and Neck Cancer CrossRef
11. In�vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines
    Stefan Holzhauser et al, 2019, Oncology Letters CrossRef
12. Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
    Geet Madhukar et al, 2021, Current Cancer Drug Targets CrossRef
13. Cancer: the dark side of wound healing
    Gopinath M. Sundaram et al, 2018, The FEBS Journal CrossRef
14. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer
    Abdulmelik Aytatli et al, 2022, Cellular Oncology CrossRef
15. Emerging tyrosine kinase inhibitors for head and neck cancer
    Zhen Long et al, 2022, Expert Opinion on Emerging Drugs CrossRef
16. Multi‑kinase inhibitors and cisplatin for head and neck cancer treatment in vitro
    Roman Brands et al, 2019, Oncology Letters CrossRef
17. New insights into RAS in head and neck cancer
    Sankar Jagadeeshan et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
18. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment
    Robert Kleszcz, 2023, Cancers CrossRef
19. In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
    Arabinda Das et al, 2020, Cancer Investigation CrossRef
20. Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling
    Yashika Jawa et al, 2021, Frontiers in Oncology CrossRef